Recursion Pharmaceuticals, Inc. (RXRX) CFO and President of Recursion UK, Ben Taylor, recently engaged in a fireside chat at the 2026 KeyBanc Capital Markets Healthcare Virtual Forum on March 17, 2026, at 3:45 PM EDT.
Fireside Chat Overview
Scott Schoenhaus, healthcare tech equity analyst at KeyBanc Capital Markets, hosted the session. He welcomed participants and introduced Taylor, noting the company’s significant changes over the past 12 to 24 months.
Schoenhaus stated, “Thanks, everyone, for joining. My name is Scott Schoenhaus. I am the health care tech equity analyst here at KeyBanc. It’s a pleasure to have Ben Taylor, CFO of Recursion, for a fireside chat.”
He encouraged Taylor to introduce himself and highlight the company’s story for newcomers.
Ben Taylor’s Background and Path to Recursion
Taylor joined Recursion via the merger with Exscientia, where he served as CFO and Chief Strategy Officer for more than four years. The companies combined 18 months ago.
“I was actually coming over from the Exscientia side of the merger,” Taylor explained. “I had been there for a little over 4 years when we brought the companies together 18 months ago.”
Before Exscientia, Taylor oversaw daily operations at an oncology biotech firm. He managed clinical trial setups, site visits, and FDA interactions, gaining deep insights into traditional drug development challenges.
This hands-on work exposed the limitations of sparse data in decision-making. Taylor observed, “What I realized is I and all of my colleagues around me… had really been guessing because the data that you have to make good decisions is so sparse.”
His banking experience earlier reinforced this, as clients often relied on incomplete information. These realizations drew him to AI-driven drug discovery, leveraging emerging data to improve accuracy.
